Originally posted on VentureBeat Big medical technology companies have the trust of hospitals. But digital-health startups are the ones developing the most exciting new technologies. Given partnerships and acquisitions lately, it looks like these two kinds of businesses can help each other.
The only FDA-approved, wearable cancer treatment device may expand its reach. A Phase III trial of Optune (NovoTTF-100A System) from Novocure was halted early due to statistically significant efficacy for the device in combination with chemotherapy to treat newly diagnosed glioblastoma patients.
(Reuters) – Talent spotters from Novartis AG, charged with bringing new ideas into the organization, are casting their net beyond biotech into the wider pool of wearable, or even edible, technology.
Baird Capital, the direct private investment arm of Robert W. Baird & Co. (Baird), announced the final close of its fourth Venture Capital fund with a total of $185 million in committed capital, exceeding its initial target of $150 million and the size of its previous fund. Fund IV was oversubscribed, anchored by support from…
First Abbott split and created AbbVie, then Baxter with Baxalta, is Amgen up next? I am placing best the new spin off will be called Pmgen. Hedge fund manager Daniel Loeb is lending his voice to the chorus of investors who believe Amgen ($AMGN) would do better as two companies. And his firm, Third Point,…
Abbott ($ABT) made separate announcements related to devices focused on the eyes. The first was for a deal it reached with Carl Zeiss Meditec to sell the Swiss lensmaker’s cataract surgery products alongside its own ocular surgery devices.